51. Analyses of Titanocenes in the spheroid-based cellular angiogenesis assay
- Author
-
Matthias Tacke, Clara Pampillón, Megan Hogan, Holger Weber, and James Claffey
- Subjects
Angiogenesis ,Drug candidate ,Swine ,Spheroid ,Titanocene dichloride ,Endothelial Cells ,Angiogenesis Inhibitors ,General Medicine ,Pharmacology ,Toxicology ,Umbilical vein ,chemistry.chemical_compound ,Titanocene Y ,chemistry ,cardiovascular system ,Cancer research ,Organometallic Compounds ,Cytotoxic T cell ,Animals ,Humans ,LLC-PK1 Cells ,Endothelium, Vascular ,Cytotoxicity ,Cells, Cultured - Abstract
Titanocene dichloride and two of its derivatives (Titanocene Y and C) were tested on human umbilical vein endothelial cells (HUVEC) sprouting in a spheroid-based cellular angiogenesis assay in order to determine IC50 values of inhibition. Titanocene dichloride and Titanocene Y inhibited HUVEC sprouting in this angiogenesis assay with IC50 values of 19 microM and 4.9 microM, while Titanocene C surprisingly showed no inhibition. This classifies Titanocene dichloride as a purely anti-angiogenic anticancer drug and Titanocene C as a purely cytotoxic anticancer drug. On the other hand, Titanocene Y combines both favourable anticancer activities and seems to be the drug candidate of choice for further optimisation.
- Published
- 2007